ImmuMap Mode-of-Action Cellular Analysis Using Multi-parameter Flow Cytometry

ImmuMap offers state-of-the-art cellular immune analysis solutions for biotech companies developing products for the treatment of immune-oncology and autoimmune diseases.

The company’s services utilise multi-parameter flow cytometry and cell culturing to optimise drug performance. It analyses data from immune monitoring and mode-of-action analyses, as well as presents findings in a consolidated report.

Multi-colour flow cytometry and cell culturing

ImmuMap provides robust assays for the delivery of pre-clinical and clinical-phase data. The assays are customised to meet specific client requirements.

The company performs assays within cell culturing, stimulation and multi-colour flow cytometry with up to 18 parameters. Specialising in the enumeration of multiple specific T-cell populations and associated maturation phenotypes, it uses specialised major histocompatibility complex (MHC) multimers in a high-end and unique assay recently established by its academic collaborators.

ImmuMap partners with several front-line biotech and academic companies, which help it stay updated in the highly complex immune-oncology and autoimmunity sectors. The company also applies its technical and theoretical immune-oncology expertise in these fields.

Immune monitoring and mode-of-action analysis

ImmuMap offers immune monitoring and mode-of-action analysis for immune-therapeutic agents or drugs, as well as T-cell epitope discovery, training courses and consultancy services.

The company communicates with clients to determine an optimal analysis package to ensure the final report contains relevant data, which is analysed and presented in an easy-to-understand layout.

Cellular therapy safety package

ImmuMap has established several assays based on flow cytometry and next-generation sequencing for measuring alloreactivity and the T-cell receptor (TCR) fingerprint.

These assays help prevent cross-reactivity and safety issues in checkpoint inhibitor antibody treatments and chimeric antigen receptor (CAR) T or TCR-transduced cell therapies, which are commonly used within immune-oncology. These treatments aim to manipulate the patients’ immune system to fight cancerous tissues.

Transparent data collection and reporting

ImmuMap can work to short deadlines and initiates new studies within a month. It provides a simple data report for immediate use, and later delivers all raw data and associated analysis files to maintain transparency and understanding in the collaboration.

The company understands the need for fast delivery and immediately provides electronic versions of the data package and reports once all experiments are complete. It also sends a printed version of the report for the customer’s archives and future reference.

For more information, please send an enquiry using the form on this page.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

ImmuMap to Offer Cellular Therapy Safety Package

Numerous companies within immune-oncology have been founded in the past years, while existing large companies have increasingly turned their attention to this field, aiming to manipulate patients’ immune system to fight cancer in different ways.

Address
ImmuMap

Diplomvej 377

2800 Kgs Lyngby

Denmark

+45 617 818 82 www.Immumap.com

ImmuMap Images

Products and Services

Video

White Papers

Related Projects



Press Release

10 December 2018

Numerous companies within immune-oncology have been founded in the past years, while existing large companies have increasingly turned their attention to this field, aiming to manipulate patients’ immune system to fight cancer in different ways.

Read more

Regional Offices

ImmuMap

Diplomvej 377

2800 Kgs Lyngby

Denmark

Thomas M. Frøsig, CEO +45 617 818 82 www.Immumap.com

Contact company

I have read and accept the terms and conditions and privacy policys.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.